Predictors of treatment outcomes following treat-and-extend regimen with aflibercept for branch retinal vein occlusion: post-hoc analysis of the PLATON trial

We investigated predictors of visual outcomes and injection interval in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) treated with a treat-and-extend (TAE) regimen. All 48 patients in a multicenter study were followed for 52 weeks and received three monthly intravitreal aflibe...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-07, Vol.13 (1), p.11730-11730, Article 11730
Main Authors: Son, Wonyung, Jeong, Woo Jin, Park, Jung Min, Kim, Jung-Yeul, Ji, Yong-Sok, Sagong, Min
Format: Article
Language:English
Subjects:
692/53/2423
692/699/3161/3175
Biomarkers
Cholesterol
Clinical outcomes
Clinical trials
Diabetes
Diabetic retinopathy
Edema
High density lipoprotein
Hospitals
Humanities and Social Sciences
Injection
Medical laboratories
multidisciplinary
Occlusion
Ophthalmology
Patients
Retina
Risk factors
Science
Science (multidisciplinary)
Success
Tomography
University colleges
Vascular endothelial growth factor
Veins & arteries
Visual acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated predictors of visual outcomes and injection interval in macular edema (ME) secondary to branch retinal vein occlusion (BRVO) treated with a treat-and-extend (TAE) regimen. All 48 patients in a multicenter study were followed for 52 weeks and received three monthly intravitreal aflibercept injections before the TAE regimen, with treatment intervals adjusted by 4 weeks, up to a maximum of 16 weeks. Various laboratory biomarkers and optical coherence tomography parameters were evaluated. Patients were classified into the extension failure group if they had ≥ 1 treatment interval decreased due to an increase in the central macular thickness compared to the previous visit and 18 patients were assigned to this group. In multivariate logistic analyses, presence of microaneurysms and prominent middle limiting membrane (p-MLM) sign, increased initial external limiting membrane (ELM) disruption, and higher total cholesterol were correlated with inhibiting a sustained extension in the injection interval ( P  = 0.015, P  = 0.032, P  = 0.037, P  = 0.009, respectively). Therefore, in the patients with ME secondary to BRVO with these risk factors, early consideration of frequent injection may improve treatment outcome.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-38955-4